An Open-label, Single Arm, Phase III Study to Assess the Self-administration of AOP2014 Using a Pre-filled Pen, Developed for the Treatment of Polycythemia Vera Patients

Trial Profile

An Open-label, Single Arm, Phase III Study to Assess the Self-administration of AOP2014 Using a Pre-filled Pen, Developed for the Treatment of Polycythemia Vera Patients

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Ropeginterferon alfa-2b (Primary)
  • Indications Polycythaemia vera
  • Focus Registrational; Therapeutic Use
  • Acronyms PEN-PV
  • Sponsors AOP Orphan Pharmaceuticals AG
  • Most Recent Events

    • 25 Jun 2017 Final results of the study presented at the 22nd Congress of the European Haematology Association.
    • 25 Jun 2017 Results published in an AOP Orphan Pharmaceuticals AG media release.
    • 25 Jun 2017 According to an AOP Orphan Pharmaceuticals AG media release, latest results from the study were presented at the 22nd Congress of the European Hematology Association (EHA) 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top